Clinical utility of ustekinumab in Crohn’s disease

The introduction of anti-tumor necrosis factor (TNF) therapy marked an important milestone in the management of moderate-to-severe Crohn’s disease (CD). However, there remains a pressing demand for alternative therapeutic options for patients with primary nonresponse, secondary loss of response, or...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotze, Paulo Gustavo, Ma, Christopher, Almutairdi, Abdulelah, Panaccione, Remo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810512/
https://www.ncbi.nlm.nih.gov/pubmed/29445293
http://dx.doi.org/10.2147/JIR.S157358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810512/
https://www.ncbi.nlm.nih.gov/pubmed/29445293
http://dx.doi.org/10.2147/JIR.S157358

Ejemplares similares